United States pharmaceutical preparations industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 16

Name: Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 16 comparison snapshot
Creator: Fliar BI Prism

A five-company pharmaceutical preparations cohort selected by Prism readiness, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 31 August 2026Not investment adviceRanked by Prism readiness

Readiness leaderAbeona Therapeutics · 45

Strongest available pathRetrophin · +173.3%

Widest latest marginAbeona Therapeutics · 1223.1%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1ABEO · Nasdaq

Abeona Therapeutics

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1974New York City, New York$334.5M market cap

View full Companies Radar profile

45Cautious

Snapshot price$5.85as of page date

Monthly-close return-79.1%five-year window

FY2025 revenue$0.01BABEONA THERAPEUTICS INC.

Net margin1223.1%FY2025

P/E snapshot-31.3xone ratio, not a verdict

Prism attention18.1%share across these five

Filing track recordRevenue, USD billions

+94.0%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 18.0%

52-week position51% through range

$4.00$7.65

News mentions1.1K

Community mentions0partial coverage

U.S.-scope patents42

Prism InsightsWhat sits behind the readiness signal
Observed risk 7/100higher means more observed risk

Earnings signal51/100
Management stability90/100
Market position3/100
Capital-event signal75/100
Innovation pulse10/100

Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 2 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2QTTB · Nasdaq

Homology Medicines

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2018Cambridge, Massachusetts$442.7M market cap

View full Companies Radar profile

45Cautious

Snapshot price$14.87as of page date

Monthly-close return-89.5%five-year window

FY2023 revenue$0.00BQ32 Bio Inc.

Net margin-9771.7%FY2023

P/E snapshot4.7xone ratio, not a verdict

Prism attention12.9%share across these five

Filing track recordRevenue, USD billions

-30.6%

FY2019–FY2023 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -8.7%

52-week position60% through range

$1.62$23.57

News mentions783

Community mentions9partial coverage

U.S.-scope patents162

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal47/100
Management stability90/100
Market position9/100
Capital-event signal65/100
Innovation pulse5/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 5 M&A involvements, 0 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3NWBO · OTC

Northwest Biotherapeutics

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1998Bethesda, Maryland$290.0M market cap

View full Companies Radar profile

45Cautious

Snapshot price$0.17as of page date

Monthly-close return-86.7%five-year window

FY2025 revenue$0.00BNORTHWEST BIOTHERAPEUTICS INC

Net margin-4365.9%FY2025

P/E snapshot-2.4xone ratio, not a verdict

Prism attention9.5%share across these five

Filing track recordRevenue, USD billions

-0.3%

FY2024–FY2025 · 2 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -0.3%

52-week position15% through range

$0.14$0.34

News mentions578

Community mentions0partial coverage

U.S.-scope patents255

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal42/100
Management stability90/100
Market position13/100
Capital-event signal75/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 5 M&A involvements, 2 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4TVTX · Nasdaq

Retrophin

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2011San Diego$6.16B market cap

View full Companies Radar profile

45Cautious

Snapshot price$66.28as of page date

Monthly-close return+173.3%five-year window

FY2025 revenue$0.49BTravere Therapeutics, Inc.

Net margin-5.2%FY2025

P/E snapshot11.7xone ratio, not a verdict

Prism attention30.4%share across these five

Filing track recordRevenue, USD billions

+115.7%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 21.2%

52-week position97% through range

$17.27$67.85

News mentions1.8K

Community mentions0partial coverage

U.S.-scope patents90

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal72/100
Management stability90/100
Market position5/100
Capital-event signal34/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 2 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5SDGR · Nasdaq

Schrodinger

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1990Paradox, Colorado$1.46B market cap

View full Companies Radar profile

45Cautious

Snapshot price$19.50as of page date

Monthly-close return-64.3%five-year window

FY2025 revenue$0.26BSchrodinger, Inc.

Net margin-40.4%FY2025

P/E snapshot-14.4xone ratio, not a verdict

Prism attention29.1%share across these five

Filing track recordRevenue, USD billions

+85.5%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Revenue derived as cost of revenue plus gross profit for FY2022 · CAGR 16.7%

52-week position71% through range

$10.95$23.02

News mentions1.8K

Community mentions3.7Kpartial coverage

U.S.-scope patents79

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal86/100
Management stability90/100
Market position0/100
Capital-event signal15/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Retrophin

+173.3%

Schrodinger

-64.3%

Abeona Therapeutics

-79.1%

Northwest Biotherapeutics

-86.7%

Homology Medicines

-89.5%

Latest revenue

USD billions, official filing scope shown on each company card.

Retrophin

$0.49B

Schrodinger

$0.26B

Abeona Therapeutics

$0.01B

Homology Medicines

$0.00B

Northwest Biotherapeutics

$0.00B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Abeona Therapeutics

1223.1%

Retrophin

-5.2%

Schrodinger

-40.4%

Northwest Biotherapeutics

-4365.9%

Homology Medicines

-9771.7%

Prism news attention

Normalized share across these five names; attention is not quality.

Retrophin

30.4%

Schrodinger

29.1%

Abeona Therapeutics

18.1%

Homology Medicines

12.9%

Northwest Biotherapeutics

9.5%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized pharmaceutical preparations news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Retrophin leads the conversation

It holds 30.4% of measured pharmaceutical preparations news attention and also carries the basket's largest revenue base at $0.49B.

Price path

Retrophin leads the available price paths

Its monthly-close return is +173.3% for the five-year window. At the other end, Homology Medicines is -89.5% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Abeona Therapeutics has the widest latest margin

Its FY2025 net margin is 1223.1%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Abeona Therapeutics shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -31.3x while its five-year window price return is -79.1%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · ABEO

Abeona Therapeutics

1,096available Prism news records

Prism top themes

Price action & investor response

Legal, arbitration & regulatory

Leadership & governance

Capital allocation & transactions

Earnings & financial performance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+14.4%231 latest 12m vs 202 prior 12m

Machine-classified coverage tone

79.1% positive-11.4 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

gene therapy rare diseases 67rare disease treatment 30rare disease clinical trials 28orphan drug exclusivity 20cell-based therapies 18stem cell banking 13orphan drug pricing 12cell therapy 11

Keyword tag occurrences in available Prism news records.

Coverage: 2013-10-10–2026-06-12 · trend and themes shown through 2026-06

Areas of research · TVTX

Retrophin

1,841available Prism news records

Prism top themes

Capital allocation & transactions

Price action & investor response

Legal, arbitration & regulatory

Earnings & financial performance

Leadership & governance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+13.9%115 latest 12m vs 101 prior 12m

Machine-classified coverage tone

86.6% positive+11.3 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

rare disease treatment 14rare disease clinical trials 6stock price 6share price 4orphan drug exclusivity 4gene therapy rare diseases 4company valuation 3orphan drug pricing 3

Keyword tag occurrences in available Prism news records.

Coverage: 2011-05-11–2026-06-04 · trend and themes shown through 2026-06

Areas of research · SDGR

Schrodinger

1,763available Prism news records

Prism top themes

Price action & investor response

Earnings & financial performance

Legal, arbitration & regulatory

Capital allocation & transactions

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-10.0%215 latest 12m vs 239 prior 12m

Machine-classified coverage tone

75.0% positive-8.7 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

machine learning drug discovery 24neural networks drug design 20drug repurposing ai 20stock performance 18drug design 17ai toxicity prediction 14stock price 13angiogenesis inhibitors 11

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-06-03 · trend and themes shown through 2026-06

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

SDGR

Schrodinger

3,668 mentions

Products, pricing and logistics

546

Stock and valuation

437

Workplace and hiring

263

Other company context

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 3,668 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

ABEO

Abeona Therapeutics

through 2025-12-15

Earnings releases 7Regulatory 4Leadership changes 3Listing / IPO 2M&A 1

2025-12-15
Leadership changes
Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice President, Chief Business Officer (CBO).
2025-08-15
Regulatory
In April 2025, the U.S. FDA approved ZEVASKYN (prademagene zamikeracel) for the treatment of wounds in adult and pediatric patients with RDEB.
2025-03-27
Earnings releases
Zacks Small Cap analyst D. Bautz forecasts that the biopharmaceutical company will post earnings per share of ($0.34) for the quarter.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

QTTB

Homology Medicines

through 2025-02-14

M&A 4Earnings releases 2Lawsuits 1Leadership changes 1

2025-02-14
Leadership changes
Homology Medicines Inc., of Bedford, Mass., added Matthew R. Patterson to its board.
2024-03-26
M&A
Q32 Bio Inc. (NASDAQ: QTTB), known for its groundbreaking work in developing biologic therapeutics aimed at restoring immune homeostasis, announced the successful completion of its merger with Homology Medicines, Inc.
2023-11-16
Earnings releases
As per the news, the Q3 earnings report came out 2 days ago.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

NWBO

Northwest Biotherapeutics

through 2026-01-14

Listing / IPO 8M&A 5Leadership changes 3Company announcements 1Earnings releases 1

2026-01-14
Earnings releases
The biotechnology company reported ($18.22) earnings per share (EPS) for the quarter. The company had revenue of $0.20 million for the quarter.
2025-10-26
M&A
Northwest Biotherapeutics, Inc. (OTCQB: NWBO), a U.S.-based biotechnology company focused on personalized dendritic cell vaccines for cancer treatment, has officially closed its acquisition of UK-based contract development and manufacturing organization (CDMO) Advent BioServices Ltd.
2025-02-14
Listing / IPO
Northwest Biotherapeutics Inc. (NWBT)6 8/13 N/A N/A N/A C.E. Unterberg, Towbin $48.3

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

TVTX

Retrophin

through 2025-02-14

Listing / IPO 2

2025-02-14
Listing / IPO
Retrophin Inc., of San Diego, said it closed its public offering of about 7.9 million shares priced at $19 apiece, including 1.03 million shares sold to cover the full overallotment option. Gross proceeds totaled about $149.5 million.
2025-02-14
Listing / IPO
Retrophin Inc. priced a public offering for expected gross proceeds of about $130 million.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

SDGR

Schrodinger

through 2025-10-21

Earnings releases 8Leadership changes 3

2025-10-21
Earnings releases
Revenues are expected to be $52.68 million, up 49.3% from the year-ago quarter.
2025-05-20
Leadership changes
Schrodinger (SDGR) announced that the company and Geoffrey Porges, MBBS., have mutually agreed that Dr. Porges will depart from his role as CFO to pursue other opportunities.
2025-05-20
Leadership changes
Richie Jain, who previously served as Schrodinger’s senior vice president, strategic finance and head of corporate and business development, will succeed Geoffrey Porges as CFO.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Pharmaceutical Preparations Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary pharmaceutical preparations news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

pharmaceutical industry

36 sources100.0% extraction confidence

2011 extracted base$66.70B

2016 extracted forecast$42.00B–$70.00B

Implied source CAGR9.5%

Macro and micro trends driving the industry's futureR&D expenditure and leading therapeutic areasGrowth opportunities

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, India, China, U.S.. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Pharmaceutical Preparations news pulse

55,282available Prism news records

Latest 12m volume+3.4%24052 vs 23272 records

Positive classified tone65.3%+6.0 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching pharmaceutical, preparation. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

drug pricing and reimbursement strategies

6,223

snowstorm and blizzard alerts

6,121

pharmaceutical marketing and sales strategies

6,014

winter weather preparedness

5,925

generic drug development and market trends

3,700

healthcare economics and market access

3,498

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

ice storm preparation 6,522snowstorm advisory 5,649cold weather readiness 5,010heavy snow warning 4,972winter storm alert 4,355snow accumulation alert 4,114life-threatening weather 2,915severe weather warning 2,905

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

Macro and micro trends driving the industry's future

36 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

drug pricing and reimbursement strategies

6,223 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

5,689 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

regulatory changes

5,709 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+3.4% news volume

The latest 12 months contain 24,052 matched records versus 23,272 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

65.3% positive · +6.0pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2834 (Pharmaceutical Preparations), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 76–83. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Pharmaceutical Preparations Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 31 August 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Abeona Therapeutics leads the readiness ranking

Its Prism readiness score is 45/100, the highest in this five-company comparison.

Open Abeona Therapeutics in Companies Radar

Scale and margin leadership sit with Retrophin and Abeona Therapeutics

Retrophin has the largest displayed latest revenue at $0.49B; Abeona Therapeutics has the widest displayed latest margin at 1223.1%.

Open Retrophin in Companies Radar Open Abeona Therapeutics in Companies Radar

Comparisons

Strongest versus weakest available price path

Retrophin is +173.3% for its five-year window; Homology Medicines is -89.5% for its five-year window.

Open Retrophin in Companies Radar Open Homology Medicines in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $0.49B for Retrophin to $0.00B for Northwest Biotherapeutics. Entity and filing-period labels remain visible on the company cards.

Open Retrophin in Companies Radar Open Northwest Biotherapeutics in Companies Radar

Anomalies

Retrophin has the widest attention-readiness rank gap

It ranks #1 by measured news attention (30.4%) and #4 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Retrophin in Companies Radar

Abeona Therapeutics shows a price-operating divergence to inspect

Its displayed filing-revenue change is +94.0% while its available monthly-close return is -79.1%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Abeona Therapeutics in Companies Radar

Explanations

Attention measures coverage volume, not quality

Retrophin's 30.4% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Retrophin in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Abeona Therapeutics's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 45/100 score.

Open Abeona Therapeutics in Companies Radar

Stress-test the largest divergence before forming a view

Compare Abeona Therapeutics's profile with Retrophin's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open Abeona Therapeutics in Companies Radar Open Retrophin in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.